KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.

Sanne A L Bartels, Mila Donker, Coralie Poncet, Nicolas Sauvé, Marieke E Straver, Cornelis J H van de Velde, Robert E Mansel, Charlotte Blanken, Lorenzo Orzalesi, Jean H G Klinkenbijl, Huub C J van der Mijle, Grard A P Nieuwenhuijzen, Sanne C Veltkamp, Thijs van Dalen, Andreas Marinelli, Herman Rijna, Marko Snoj, Nigel J Bundred, Jos W S Merkus, Yazid Belkacemi, Patrick Petignat, Dominic A X Schinagl, Corneel Coens, Geertjan van Tienhoven, Frederieke van Duijnhoven, Emiel J T Rutgers

J Clin Oncol 41(12) 2159-2165

PMID36383926
PMCID-
DOI10.1200/JCO.22.01565
发表日期2022-11-16
入排依据:The study meets criteria for being an oncology, human, randomized, Phase III trial with original primary results and time-to-event efficacy endpoints (OS, DFS). However, it is excluded because both interventions are non-drug (surgical/radiotherapeutic), and the requirement is for a drug-containing intervention.
摘要

摘要

PURPOSE: The European Organisation for Research and Treatment of Cancer 10981-22023 AMAROS trial evaluated axillary lymph node dissection (ALND) versus axillary radiotherapy (ART) in patients with cT1-2, node-negative breast cancer and a positive sentinel node (SN) biopsy. At 5 years, both modalities showed excellent and comparable axillary control, with significantly less morbidity after ART. We now report the preplanned 10-year analysis of the axillary recurrence rate (ARR), overall survival (OS), and disease-free survival (DFS), and an updated 5-year analysis of morbidity and quality of life. METHODS: In this open-label multicenter phase III noninferiority trial, 4,806 patients underwent SN biopsy; 1,425 were node-positive and randomly assigned to either ALND (n = 744) or ART (n = 681). RESULTS: Per intention-to-treat analysis, 10-year ARR cumulative incidence was 0.93% (95% CI, 0.18 to 1.68; seven events) after ALND and 1.82% (95% CI, 0.74 to 2.94; 11 events) after ART (hazard ratio [HR], 1.71; 95% CI, 0.67 to 4.39). There were no differences in OS (HR, 1.17; 95% CI, 0.89 to 1.52) or DFS (HR, 1.19; 95% CI, 0.97 to 1.46). ALND was associated with a higher lymphedema rate in updated 5-year analyses (24.5% v 11.9%; P < .001). Quality-of-life scales did not differ by treatment through 5 years. Exploratory analysis showed a 10-year cumulative incidence of second primary cancers of 12.1% (95% CI, 9.6 to 14.9) after ART and 8.3% (95% CI, 6.3 to 10.7) after ALND. CONCLUSION: This 10-year analysis confirms a low ARR after both ART and ALND with no difference in OS, DFS, and locoregional control. Considering less arm morbidity, ART is preferred over ALND for patients with SN-positive cT1-2 breast cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。